• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Impact of pre ‐existing or new‐onset atrial fibrillation on 30‐day clinical outcomes following Transcatheter Aortic Valve Replacement: Results From The BRAVO 3 Randomized Trial
Conclusions: Prior or new‐onset AF within 30 days of transfemoral TAVR is noted in more than one‐third of patients. Despite greater baseline comorbidities than non‐AF patients, AF was not associated with greater risk of adjusted 30‐day outcomes. In the BRAVO 3 trial, early outcomes were similar regardless of anticoagulant strategy in each group. This article is protected by copyright. All rights reserved.
Source: Catheterization and Cardiovascular Interventions - May 1, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Christian Hengstenberg, Jaya Chandrasekhar, Samantha Sartori, Thierry Lefevre, Ghada Mikhail, Nicolas Meneveau, Christophe Tron, Raban Jeger, Christian Kupatt, Birgit Vogel, Serdar Farhan, Sabato Sorrentino, Madhav Sharma, Clayton Snyder, Oliver Husser, P Tags: VSD ‐ Valvular and Structural Heart Diseases Source Type: research

Sex ‐Based Differences In Outcomes With Bivalirudin Or Unfractionated Heparin For Transcatheter Aortic Valve Replacement: Results From The BRAVO 3 Randomized Trial
Conclusions: There was no difference in early outcomes with bivalirudin versus UFH in men or women undergoing contemporary TAVR. This article is protected by copyright. All rights reserved.
Source: Catheterization and Cardiovascular Interventions - June 30, 2016 Category: Cardiovascular & Thoracic Surgery Authors: A Asgar, J Chandrasekhar, G Mikhail, J Webb, T Lefevre, C Tamburino, D Hildick ‐Smith, R Hambrecht, E Van Belle, J Widder, N Dumonteil, U Hink, R Jeger, A Linke, E Dellargyris, P Gao, R Mehran, C Hengstenberg, P Anthopoulos, G Dangas, Tags: Original Studies Source Type: research

Sex‐Based Differences In Outcomes With Bivalirudin Or Unfractionated Heparin For Transcatheter Aortic Valve Replacement: Results From The BRAVO 3 Randomized Trial
Conclusions: There was no difference in early outcomes with bivalirudin versus UFH in men or women undergoing contemporary TAVR. This article is protected by copyright. All rights reserved.
Source: Catheterization and Cardiovascular Interventions - April 30, 2016 Category: Cardiovascular & Thoracic Surgery Authors: A Asgar, J Chandrasekhar, G Mikhail, J Webb, T Lefevre, C Tamburino, D Hildick‐Smith, R Hambrecht, E Van Belle, J Widder, N Dumonteil, U Hink, R Jeger, A Linke, E Dellargyris, P Gao, R Mehran, C Hengstenberg, P Anthopoulos, G Dangas, Tags: Original Studies Source Type: research